JPM26: Leo Pharma's growth strategy puts a spotlight on rare dermatology diseases [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
The CEO, Christophe Bourdon, discussed that he was there to make deals focused on assets in rare disease space within dermatology. Leo's dermatology focused portfolio and R&D strength enables the company to lead innovation in the rare dermatology space in indications previously deprioritised to advance the marketing of drugs in highly prevalent conditions such as atopic dermatitis. Among Leo's leading marketed products are Adbry (tralokinumab) approved for use in patients with moderate to severe atopic dermatitis, and Anzupgo (delgocitinib), which was approved as first-in-class topical JAK inhibitor for chronic hand eczema. In the wider context, atopic dermatitis (AD) represents a growing and evolving market with unmet needs including effective treatments that are longer acting. However, with multiple players within AD (both within biologics and topicals), it is also an area that has a high level of competition in the market. This complexity necessitates the need for clinical diff
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi (NASDAQ:SNY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Sanofi (NASDAQ:SNY) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.MarketBeat
- State Street's crypto push, FDA delays review of Eli Lilly GLP-1 [Yahoo! Finance Canada]Yahoo! Finance Canada
- Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix [Seeking Alpha]Seeking Alpha
- Novavax (NVAX) Is Up 7.5% After Pivot To Partner-Led Model And Sanofi Collaboration - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 1/16/26 - Form 6-K
- 1/9/26 - Form 6-K
- 12/29/25 - Form 6-K
- SNY's page on the SEC website